Apr, 05 2019 10:45 JST

Source: Eisai

Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug

Motion Sickness Solution Now Available in Convenience Stores

TOKYO, Apr, 05 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch the mouth freshener Travelmin Support as the first quasi-drug of the Travelmin series which can be purchased even at convenience stores and others in Japan on Monday, April 8.

Travelmin Support is a quasi-drug that contains plant derived daylily extract as its main ingredient to help with motion sickness and discomfort. As a drop-type product, it is easy for children to take, and it has a refreshing cider flavor. Each drop is individually wrapped for convenience, is easy to carry around, and can be taken by both adults and children five of age and older.

After hearing the voices of many consumers who had difficulties because they forgot to purchase motion sickness medicine and were unable to obtain any during their travels, Eisai decided to launch Travelmin Support as a quasi-drug that can be purchased even at convenience stores and others.

The Travelmin series is widely familiar in Japan as a national brand of motion sickness medicines. In addition to Travelmin, which was introduced in 1952, Eisai has launched the drop-type product Travelmin Churop (class 2 pharmaceutical product) which can be taken even after becoming sick, Travelmin R (class 2 pharmaceutical product) which contains ingredients that comparatively cause less sleepiness, and others. With the introduction of Travelmin Support to the Travelmin lineup, Eisai will continue to contribute to people concerned about motion sickness and discomfort when traveling, as well as help consumers enjoy their travels.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: HealthCare

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019
July 18 2019 13:26 JST
 
Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019
July 18 2019 12:01 JST
 
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
July 17 2019 08:20 JST
 
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
July 11 2019 12:59 JST
 
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
July 11 2019 09:04 JST
 
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
July 10 2019 12:27 JST
 
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery
July 08 2019 09:31 JST
 
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
June 18 2019 12:32 JST
 
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress
June 18 2019 12:11 JST
 
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
May 29 2019 09:05 JST
 
More Press release >>

Latest Press Release


More Latest Release >>